Scienjoy Holding H1 Income Rises

Scienjoy Holding Corp (SJ) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Scienjoy Holding Corporation Reports Second Quarter and First Half 2026 Unaudited Financial Results BEIJING, October 26, 2026 /PRNewswire/ -- Scienjoy Holding Corporation (“Scienjoy”, the “Company”, or “we”) (NASDAQ: SJ), an AI technology company powered by a dual en

Stella-Jones (TSX:SJ) shares fell about 25% from roughly $100 earlier this year to around $75 after its latest quarterly results disappointed investors, according to the article. Net income dropped to $60 million ($1.10/share) from $1.67/share a year earlier, while revenue rose from $773 million to $791 million. The article attributes the profit decline to lower gross margin (21.7% to 19.6%) from product mix, pricing pressure, and higher input costs.

Deutsche Bank reported its third consecutive record quarterly profit, with pre-tax earnings rising 8% year-on-year to €2.6B. Net profit reached €1.9B, up 2% from the same period last year. The bank's investment banking division contributed significantly, with a pre-tax profit of nearly €1.1B, up 12% from a year earlier. Deutsche Bank expects annual revenue to exceed €33B in 2026.

Piper Sandler downgraded F5 Networks (FFIV) to Neutral, citing valuation concerns despite strong Q4 results. The stock is up 80% YTD, trading at $459.36. Piper maintains a $461 price target, noting potential peaking growth and lack of catalysts. F5 reported Q4 adjusted earnings of $4.42 per share, beating estimates, with revenue of $917M, up 13% YoY.

Stifel downgraded Whirlpool (WHR) to Sell, lowering its price target to $20 from $30, citing market share losses and near-term challenges. The company's Q3 2026 earnings missed expectations, with EPS of -$0.21 vs. $1.04 forecast and revenue of $3.68B vs. $3.97B. WHR shares are down 64% over the past year, trading at $27.42.

GSK reported Q3 sales growth of 5% to £8.9 billion, driven by specialty medicines. Core operating profit rose 5% to £3.1 billion, but total profit fell 16% due to £328 million restructuring costs. The company maintained its 2026 guidance, with sales expected to grow 3-5% and core operating profit 7-9%. Net debt increased to £20.7 billion. GSK's CEO highlighted strong quarterly performance.